Full Press Release Details
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2
adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x1015 total vg) with dosing scheduled for Q2 2024
Dosed second pediatric patient in
cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 pediatric trial in Q1 2024
FDA granted Regenerative Medicine Advanced Therapy designation following review of available safety and efficacy data from the first three
patients dosed with the low dose of TSHA-102 across both REVEAL trials (adolescent/adult and pediatric)
Initial data from cohort one (low dose, 5.7x1014 total vg) in REVEAL pediatric trial and
update from cohort one in REVEAL adolescent and adult trial expected mid-2024; initial data from cohort two (high dose, 1x1015 total vg) in both trials
(adolescent/adult and pediatric) expected in 2H 2024
Conference call and live webcast today at 4:30 PM Eastern Time
Dallas May 14, 2024 Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology
company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the first quarter ended March 31, 2024, and provided a
We are pleased with the recent progress we have made to advance our TSHA-102 program in
clinical evaluation for Rett syndrome, including enrolling the first patient in the high dose cohort of our REVEAL adolescent and adult trial earlier than planned and dosing the second patient in our REVEAL pediatric trial. We recently
received RMAT designation for TSHA-102 following the FDA s review of safety and efficacy data from the first three patients dosed with the low dose of TSHA-102
across both of our REVEAL trials, which we believe reinforces the therapeutic potential of TSHA-102, said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. We look forward to the year
ahead as we remain focused on moving to the high dose cohort and generating critical longer-term clinical data across a broad population of patients with Rett syndrome that will guide the next phase of our studies. We expect to report initial
clinical data from our REVEAL pediatric trial and provide an update on the completed low dose cohort from our REVEAL adolescent and adult trial in mid-2024.
Recent Corporate and Program Highlights
Regenerative Medicine Advanced Therapy (RMAT) designation for TSHA-102 from the United States Food and Drug Administration (FDA): A regenerative medicine therapy is eligible for RMAT designation if it is
intended to treat, modify, reverse or cure a serious condition and preliminary clinical evidence indicates the therapy has the potential to address unmet medical needs for such condition. RMAT designation follows the FDA s review of available
safety and efficacy data from the first three patients with Rett syndrome dosed with the low dose of TSHA-102 across the REVEAL Phase 1/2 adolescent and adult trial and the REVEAL Phase 1/2 pediatric trial.
RMAT designation will enable increased dialogue with the FDA to support the potential expedited development and review of TSHA-102.
REVEAL Phase 1/2 Adolescent and Adult Trial (Canada and U.S.): a first-in-human, open-label, randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of
TSHA-102 in adolescent and adult females aged 12 years and older with Rett syndrome due to MECP2 loss-of-function
mutation. TSHA-102 is administered as a single lumbar intrathecal injection. Dose escalation will evaluate two dose levels of TSHA-102 sequentially. The maximum
tolerated dose (MTD) or maximum administered dose (MAD) established in Part A will then be administered during dose expansion in Part B of the study.
REVEAL Phase 1/2 Pediatric Trial (U.S. and U.K.): an open-label,
randomized, dose-escalation and dose-expansion study evaluating the safety and preliminary efficacy of TSHA-102 in pediatric females with Rett syndrome due to MECP2 loss-of-function mutation. TSHA-102 is administered as a single lumbar intrathecal injection. Part A of the study will focus on determining MAD and MTD in patients aged
5 to 8 years old. Part B is the dose expansion phase and will evaluate TSHA-102 at the MAD or MTD in two age cohorts (5 to 8 years and 3 to 5 years).
Anticipated 2024 Milestones
First Quarter 2024 Financial
Research and Development Expenses: Research and development expenses were $20.7 million for the three months ended
March 31, 2024, compared to $12.5 million for the three months ending March 31, 2023. The $8.2 million increase was primarily driven by an increase in Good Manufacturing Practice (GMP) batch activities during the three months
ended March 31, 2024, which is representative of the intended commercial manufacturing process for TSHA-102. Additionally, clinical trial expenses increased primarily due to ongoing activities in the
REVEAL adolescent/adult and pediatric trials.
General and Administrative Expenses: General and administrative expenses were $7.1 million
for the three months ended March 31, 2024, compared to $8.8 million for the three months ended March 31, 2023. The decrease of $1.7 million was due to reduced general and administrative compensation as a result of lower headcount
and a reduction in consulting and professional fees.
Net loss: Net loss for the three months ended March 31, 2024, was
$24.1 million, or $0.10 per share, as compared to a net loss of $17.6 million, or $0.28 per share, for the three months ended March 31, 2023.
Cash and cash equivalents: As of March 31, 2024, Taysha had $124.0 million in cash and cash equivalents. Taysha continues to expect that
its current cash resources will support planned operating expenses and capital requirements into 2026.
Conference Call and Webcast Information
Taysha management will hold a conference call and webcast today at 4:30 p.m. ET to review its financial and operating results and provide a
corporate update. The dial-in number for the conference call is 877-407-0792 (U.S./Canada) or 201-689-8263 (international). The conference ID for all callers is 13745689. The live webcast and replay may be accessed by visiting Taysha s website
TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical
evaluation for Rett syndrome. Designed as a one-time treatment, TSHA-102 aims to address the genetic root cause of the disease by delivering a functional form of
MECP2 to cells in the CNS. TSHA-102 utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Regenerative Medicine Advanced Therapy, Fast Track and Orphan
Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway designation from the Medicines and Healthcare products Regulatory Agency.
Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene encoding
methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and
respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression,
plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root
cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K.
About Taysha Gene Therapies
Taysha Gene Therapies
(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program
TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on
developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company s management team has proven experience in gene therapy development and
commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
anticipates, believes, expects, intends, projects, plans, and future or similar expressions are intended to identify forward-looking statements. Forward-looking
statements include statements concerning the potential of TSHA-102, including the reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, and our
other product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, including the timing of initiating additional
trials and reporting data from our clinical trials, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and our current cash resources supporting our planned operating
expenses and capital requirements into 2026. Forward-looking statements are based on management s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from
those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
Risks regarding our business are described in detail in our Securities and Exchange Commission ( SEC ) filings, including in our Annual Report on Form 10-K for the full-year ended December 31,
2023, which is available on the SEC s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and we
disclaim any obligation to update these statements except as may be required by law.
Taysha Gene Therapies, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| For the Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | $ | 3,411 | $ | 4,706 | ||||
| Operating expenses: | ||||||||
| Research and development | 20,657 | 12,514 | ||||||
| General and administrative | 7,084 | 8,751 | ||||||
| Total operating expenses | 27,741 | 21,265 | ||||||
| Loss from operations | (24,330 | ) | (16,559 | ) | ||||
| Other income (expense): | ||||||||
| Change in fair value of warrant liability | (337 | ) | ||||||
| Change in fair value of term loan | (1,053 | ) | ||||||
| Interest income | 1,693 | 319 | ||||||
| Interest expense | (29 | ) | (1,374 | ) | ||||
| Other expense | (5 | ) | (8 | ) | ||||
| Total other income (expense), net | 269 | (1,063 | ) | |||||
| Net loss | $ | (24,061 | ) | $ | (17,622 | ) | ||
| Net loss per common share, basic and diluted | $ | (0.10 | ) | $ | (0.28 | ) | ||
| Weighted average common shares outstanding, basic and diluted | 231,249,344 | 63,260,905 |
Taysha Gene Therapies, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands, except share and per share data)
| March 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 123,980 | $ | 143,940 | ||||
| Restricted cash | 449 | 449 | ||||||
| Prepaid expenses and other current assets | 4,168 | 3,479 | ||||||
| Assets held for sale | 2,000 | 2,000 | ||||||
| Total current assets | 130,597 | 149,868 | ||||||
| Restricted cash | 2,151 | 2,151 | ||||||
| Property, plant and equipment, net | 10,686 | 10,826 | ||||||
| Operating lease right-of-use assets | 9,261 | 9,582 | ||||||
| Other non-current assets | 304 | 304 | ||||||
| Total assets | $ | 152,999 | $ | 172,731 | ||||
| LIABILITIES AND STOCKHOLDERS EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 10,380 | $ | 6,366 | ||||
| Accrued expenses and other current liabilities | 13,562 | 12,284 | ||||||
| Deferred revenue | 14,695 | 18,106 | ||||||
| Total current liabilities | 38,637 | 36,756 | ||||||
| Term loan, net | 40,512 | 40,508 | ||||||
| Operating lease liability, net of current portion | 18,499 | 18,953 | ||||||
| Other non-current liabilities | 1,502 | 1,577 | ||||||
| Total liabilities | 99,150 | 97,794 | ||||||
| Stockholders equity | ||||||||
| Preferred stock, $0.00001 par value per share; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||||||||
| Common stock, $0.00001 par value per share; 400,000,000 shares authorized and 187,018,275 and 186,960,193 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 2 | 2 | ||||||
| Additional paid-in capital | 591,166 | 587,942 | ||||||
| Accumulated other comprehensive loss | (251 | ) | ||||||
| Accumulated deficit | (537,068 | ) | (513,007 | ) | ||||
| Total stockholders equity | 53,849 | 74,937 | ||||||
| Total liabilities and stockholders equity | $ | 152,999 | $ | 172,731 |
Director, Head of Corporate Communications and
Taysha Gene Therapies, Inc.